X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1700) 1700
administration, intravesical (1414) 1414
urology & nephrology (986) 986
urinary bladder neoplasms - drug therapy (948) 948
male (946) 946
female (913) 913
bladder cancer (817) 817
index medicus (779) 779
aged (756) 756
middle aged (700) 700
urinary bladder neoplasms - pathology (700) 700
cancer (657) 657
urinary bladder neoplasms - therapy (558) 558
chemotherapy (440) 440
bacillus-calmette-guerin (417) 417
oncology (417) 417
urinary bladder neoplasms - surgery (408) 408
aged, 80 and over (391) 391
bcg vaccine - administration & dosage (372) 372
tumors (364) 364
treatment outcome (363) 363
bcg vaccine - therapeutic use (362) 362
intravesical chemotherapy (361) 361
mitomycin-c (360) 360
adult (359) 359
recurrence (354) 354
transitional-cell carcinoma (344) 344
carcinoma, transitional cell - drug therapy (337) 337
immunotherapy (334) 334
carcinoma (323) 323
antineoplastic agents - administration & dosage (304) 304
urology (303) 303
therapy (299) 299
care and treatment (292) 292
intravesical therapy (288) 288
combined modality therapy (278) 278
carcinoma, transitional cell - pathology (270) 270
follow-up studies (263) 263
animals (257) 257
neoplasm recurrence, local - prevention & control (251) 251
transurethral resection (249) 249
neoplasm staging (246) 246
neoplasm invasiveness (244) 244
carcinoma, transitional cell - therapy (233) 233
bcg (222) 222
time factors (206) 206
urothelial carcinoma (206) 206
cystectomy (205) 205
bladder (203) 203
mitomycin - administration & dosage (202) 202
antibiotics, antineoplastic - administration & dosage (201) 201
risk factors (200) 200
prognosis (198) 198
progression (197) 197
antineoplastic agents - therapeutic use (191) 191
disease progression (191) 191
transitional-cell-carcinoma (191) 191
mitomycin (185) 185
carcinoma, transitional cell - surgery (183) 183
prospective studies (181) 181
risk (179) 179
bacillus calmette-guerin (178) 178
retrospective studies (174) 174
chemotherapy, adjuvant (170) 170
bcg vaccine - adverse effects (166) 166
doxorubicin - administration & dosage (165) 165
urinary bladder neoplasms - mortality (161) 161
analysis (154) 154
disease-free survival (152) 152
research (151) 151
neoplasm recurrence, local (150) 150
pharmacology & pharmacy (149) 149
follow-up (145) 145
bladder neoplasms (141) 141
intravesical instillation (136) 136
management (136) 136
antineoplastic combined chemotherapy protocols - therapeutic use (133) 133
in-situ (133) 133
health aspects (132) 132
epirubicin (129) 129
urinary bladder neoplasms - prevention & control (127) 127
radical cystectomy (123) 123
cystoscopy (122) 122
adjuvants, immunologic - administration & dosage (121) 121
mitomycin c (117) 117
adjuvants, immunologic - therapeutic use (116) 116
drug administration schedule (116) 116
superficial bladder-cancer (116) 116
drug therapy (115) 115
urinary bladder - pathology (115) 115
superficial bladder cancer (114) 114
urinary bladder neoplasms - diagnosis (112) 112
epirubicin - administration & dosage (111) 111
neoplasm recurrence, local - epidemiology (111) 111
mitomycin - therapeutic use (106) 106
instillation (105) 105
medicine & public health (105) 105
urinary-bladder (105) 105
neoplasm recurrence, local - pathology (103) 103
surgery (102) 102
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1984) 1984
Japanese (95) 95
French (52) 52
German (51) 51
Spanish (39) 39
Italian (18) 18
Russian (13) 13
Chinese (9) 9
Dutch (3) 3
Bulgarian (2) 2
Czech (2) 2
Turkish (2) 2
Danish (1) 1
Hungarian (1) 1
Lithuanian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Urology, ISSN 0302-2838, 2007, Volume 52, Issue 4, pp. 1123 - 1130
Journal Article
European Urology, ISSN 0302-2838, 2015, Volume 69, Issue 2, pp. 231 - 244
Journal Article
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 2/2019, Volume 145, Issue 2, pp. 487 - 494
Comparing intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone in the treatment of T1-staged Grade 3... 
Transurethral resection of bladder tumor | Medicine & Public Health | Hematology | Intra-arterial chemotherapy | Intravesical chemotherapy | Oncology | Cancer Research | Internal Medicine | Bladder cancer | T1G3 | BACILLUS-CALMETTE-GUERIN | METAANALYSIS | UROTHELIAL CARCINOMA | GUIDELINES | RISK | EPIRUBICIN | CISPLATIN | ONCOLOGY
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 06/2017, Volume 79, Issue 6, pp. 1099 - 1107
Objective To compare intra-arterial chemotherapy combined with intravesical chemotherapy with intravesical chemotherapy alone in the treatment of high-risk... 
High-risk non-muscle invasive bladder cancer | Intra-arterial chemotherapy | Thulium laser | Intravesical chemotherapy | BACILLUS-CALMETTE-GUERIN | UROTHELIAL CARCINOMA | INVOLVEMENT | PRESERVATION THERAPY | INFUSION CHEMOTHERAPY | CARCINOMA IN-SITU | ARTERIAL INFUSION | ONCOLOGY | PHARMACOLOGY & PHARMACY | RADIOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Thulium | Urinary Bladder Neoplasms - diagnostic imaging | Aged, 80 and over | Female | Laser Therapy - methods | Combined Modality Therapy | Urinary Bladder Neoplasms - surgery | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Cystectomy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Urinary Bladder Neoplasms - therapy | Aged | Neoplasm Recurrence, Local - epidemiology | Administration, Intravesical | Injections, Intra-Arterial | Anthracyclines | Chemotherapy | Comparative analysis | Bladder cancer | Surgery | Cancer | Risk groups | Invasiveness | Risk reduction | Bladder | Risk | Histology | Regression analysis | Patients | Survival | Cisplatin | Urinary bladder | Epirubicin
Journal Article
Journal Article
Clinical Genitourinary Cancer, ISSN 1558-7673, 10/2019, Volume 17, Issue 5, pp. e1003 - e1010
Non–muscle-invasive bladder cancer (NMIBC) can be treated using transurethral resection (TUR), but high incidence of intravesical recurrence remains a clinical... 
Intravesical recurrence | Prevention | Transurethral resection | Epirubicin | BCG | BACILLUS-CALMETTE-GUERIN | GUIDELINES | RISK | TUMORS | ONCOLOGY | UROLOGY & NEPHROLOGY | RECURRENCE | CARCINOMA | INTRAVESICAL EPIRUBICIN | Usage | Chemotherapy | BCG vaccines | Drug therapy | Bladder cancer | Risk factors | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2017, Volume 12, Issue 4, p. e0175494
Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent progression and recurrence of non-muscle invasive bladder cancer... 
SURVIVAL | BACILLUS-CALMETTE-GUERIN | THERAPY | IMMUNOTHERAPY | MULTIDISCIPLINARY SCIENCES | GROWTH | REGULATORY T-CELLS | SUPPRESSOR-CELLS | CARCINOMA | TUMOR-IMMUNITY | GEMCITABINE | Adjuvants, Immunologic - administration & dosage | Adjuvants, Immunologic - pharmacology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Deoxycytidine - pharmacology | Urinary Bladder Neoplasms - chemically induced | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neoplasms, Experimental - immunology | Butylhydroxybutylnitrosamine - adverse effects | Female | Gene Expression Regulation, Neoplastic - drug effects | Doxorubicin - administration & dosage | Cytokines - metabolism | Deoxycytidine - administration & dosage | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Mitomycin - pharmacology | Animals | Urinary Bladder Neoplasms - immunology | Mice | Administration, Intravesical | Mitomycin - administration & dosage | Neoplasms, Experimental - drug therapy | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Antimitotic agents | Care and treatment | Dosage and administration | Antineoplastic agents | Bladder cancer | Immune response | Cytokines | Lung cancer | Lymphocytes T | Cancer therapies | Urology | Chemotherapy | Immunotherapy | Ligands | Tumor necrosis factor-TNF | Laboratory animals | Immune system
Journal Article
Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 2017, Volume 35, Issue 2, pp. 38.e9 - 38.e15
Journal Article